your badges 52W Range $32–$118 64% of range Analyst Rating BUY 22 analysts Price Target $141 +61% upside P/E -20.8 ROE -40.8% Net Profit Margin -7973.3%

DNTH Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $87.33
Market Cap (MRQ) $4.79B
P/E -20.8
EPS $-4.20
Revenue $2M
ROE -40.8%
52W Range $32–$118

DNTH Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About Dianthus Therapeutics, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees92 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$2M
2016-12-31 → 2025-12-31
EPS$-4.20
2020-12-31 → 2025-12-31
Free Cash Flow·
2018-12-31 → 2021-12-31
Net margin-7973.3%
2024-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend DNTH 5Y avg Peer Median Verdict
P/E -20.85Y avg ≈-14.9 ≈-14.9 · ·
P/S 1854.05Y avg ≈346.1 ≈346.1 55.0 Overvalued
P/B (MRQ) 4.15Y avg ≈7.6 ≈7.6 8.1 Undervalued
Price / Cash Flow -29.25Y avg ≈-24.2 ≈-24.2 · ·
Price / Tangible Book 7.75Y avg ≈2.1 ≈2.1 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -2.5%
Next Report Nov 03, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 6, 2026 $-0.90 $-0.87 -2.9%
March 31, 2026 May 11, 2026 $-0.85 $-1.09 22.3%
Dec. 31, 2025 $-1.43 $-1.10 -30.3%
Sept. 30, 2025 $-0.97 $-0.88 -10.3%
June 30, 2025 $-0.88 $-0.89 1.0%
March 31, 2025 $-0.82 $-0.87 5.3%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 14
Metric Trend 202520242023202220212020201920182017
Revenue $2M$6M$3M···$0$0$0
R&D Expense $146M$83M$33M$29M$47M$51M$59M$41M$28M
SG&A Expense $34M$25M$18M$7M$28M$28M$24M$19M$8M
Operating Expenses $180M$108M$51M$36M$75M$79M$83M$60M$36M
Operating Income $-178M$-102M$-48M$-30M$-75M$-79M$-83M$-60M$-36M
Interest Income $16M$17M$5M······
Other Non-op $-974.0K$-554.0K$-60.0K$-52.0K···$2M$236.0K
Income Tax $0$0$0$0$0$0$0$0$0
Net Income $-162M$-85M$-44M$-28M$-71M$-75M$-77M$-58M$-35M
EPS (Basic) $-4.20$-2.55$-8.45$-32.57$-1.29$-1.71···
EPS (Diluted) $-4.20$-2.55$-8.45$-32.57$-1.29$-1.71···
Shares (Basic) 38,617,58033,313,8495,153,423874,23454,948,80843,920,121···
Shares (Diluted) 38,617,58033,313,8495,153,423874,23454,948,80843,920,121···
EBITDA $-178M$-102M$-48M·$-73M$-77M$-81M$-59M·
Balance Sheet 22
Metric Trend 202520242023202220212020201920182017
Cash & Equivalents $51M$23M$132M$15M$132M$58M$65M$58M$51M
Short-term Investments $353M$252M$41M$60M$45M$91M$81M$84M·
Receivables $52.0K$0$294.0K$5M·····
Prepaid Expense $5M$5M$3M$905.0K$4M$3M$4M$3M$936.0K
Other Current Assets $86.0K$355.0K$0······
Current Assets $409M$281M$177M$82M$181M$152M$150M$145M$53M
PP&E (Net) $296.0K$194.0K$185.0K$142.0K$7M$8M$10M$10M$2M
PP&E (Gross) $600.0K$387.0K$282.0K$172.0K$14M$13M$13M$11M$2M
Accum. Depreciation $304.0K$193.0K$97.0K$30.0K$7M$5M$3M$1M$382.0K
Other Non-current Assets ········$4.0K
Total Assets $531M$374M$179M$83M$190M$162M$162M$157M$54M
Accounts Payable $10M$5M$3M$1M$3M$4M$3M$3M$167.0K
Accrued Liabilities $19M$13M$7M$7M$8M$8M$11M$7M$4M
Current Liabilities $31M$18M$10M$8M$11M$11M$14M$10M$4M
Capital Leases $1M$1M$168.0K$438.0K$0····
Total Liabilities $38M$22M$11M$9M$17M$18M$20M$12M$4M
Common Stock $43.0K$31.0K$15.0K$0$59.0K$49.0K$39.0K$33.0K$2.0K
Retained Earnings $-337M$-174M$-89M$-46M$-326M$-254M$-179M$-103M$-45M
AOCI $489.0K$106.0K$47.0K$-161.0K$-30.0K$-23.0K$8.0K$-8.0K·
Stockholders' Equity $493M$352M$169M$-44M$-17M$144M$141M$146M$-42M
Liabilities + Equity $531M$374M$179M$83M$190M$162M$162M$157M$54M
Shares Outstanding 43,223,09031,115,34114,817,696875,27958,799,15748,533,13539,260,53233,305,0332,351,247
Cash Flow 12
Metric Trend 202520242023202220212020201920182017
D&A ···$2M$2M$2M$2M$875.0K$376.0K
Stock-based Comp $23M$13M$3M$2M$10M$10M$10M$11M$2M
Other Non-cash ····$-723.0K$-1M$8M$4M·
Operating Cash Flow $-129M$-78M$-37M$-29M$-60M$-64M$-57M$-42M$-22M
CapEx ···$314.0K$1M$400.0K$3M$8M$2M
Investing Cash Flow $-123M$-287M$20M$-60M$43M$-11M$2M$-92M$-2M
Stock Issued $317.0K$0$0$3M$0$65M$61M$93M·
Net Stock Activity $317.0K$39M···$65M$61M··
Financing Cash Flow $280M$256M$134M$97M$90M$68M$62M$142M$71M
Net Change in Cash $28M$-109M$117M$8M$73M$-7M$7M$9M$47M
Taxes Paid $0$0$0$0·····
Free Cash Flow ····$-61M$-64M$-60M$-50M·
Profitability 5
Metric Trend 202520242023202220212020201920182017
Operating Margin -8739.3%-1633.7%·······
Net Margin -7973.3%-1362.8%·······
EBITDA Margin -8739.3%-1633.7%·······
ROA -35.9%-30.7%-33.2%·-40.5%-46.4%-48.2%-54.3%·
ROE -40.8%-24.6%-25.1%·-39.3%-49.5%-50.7%-37.7%·
Liquidity & Solvency 2
Metric Trend 202520242023202220212020201920182017
Current Ratio 13.315.218.4·16.613.310.613.9·
Quick Ratio 13.215.018.1·16.313.010.313.7·
Efficiency 2
Metric Trend 202520242023202220212020201920182017
Asset Turnover 0.00.0····0.00.0·
Receivables Turnover 78.311.3·······
Per Share 6
Metric Trend 202520242023202220212020201920182017
Book Value / Share $11.42$11.33$11.40·$2.94$2.97$3.60$4.37·
Revenue / Share $0.05$0.19·······
Cash Flow / Share $-3.34$-2.35$-7.15·$-1.08····
Cash / Share $1.18$0.73$8.93·$2.24$1.20$1.66$1.75·
Dividend / Share $0.00$0.00$0.00······
EPS (TTM) $-4.20$-2.55$-8.45$-32.57$-1.29$-1.71···
Growth Rates 1
Metric Trend 202520242023202220212020201920182017
Revenue YoY -67.3%120.6%·······
Valuation (TTM) 10
Metric Trend 202520242023202220212020201920182017
Revenue TTM $2M$6M$3M·$0$0$0$0·
Net Income TTM $-162M$-85M$-44M$-28M$-71M$-75M$-77M$-58M·
Market Cap $1.78B$678M$154M·$4.17B$6.09B$9.52B$3.04B·
P/E -9.8-8.5-1.2-0.2-54.9-73.4···
P/S 874.9108.854.5······
P/B 3.61.90.9·24.142.367.420.9·
P / Tangible Book 3.61.90.9··42.3···
P / Cash Flow -13.8-8.7-4.2·-70.0-95.1-166.8-72.5·
P / FCF ····-68.6-94.5-158.3-61.3·
Earnings Yield -10.2%-11.7%-81.2%-508.9%-1.8%-1.4%···

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $2M $6M $3M · ·
Operating Margin % -8739.3% -1633.7% · · ·
Net Income $-162M $-85M $-44M $-28M $-71M
Diluted EPS $-4.20 $-2.55 $-8.45 $-32.57 $-1.29

Institutional owners (13F) 284 filers · $5.9B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 284
Value held $5.9B
New positions 61
Exited positions 31
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
61 (-43 vs prior Q) 31 (+14 vs prior Q) 121 (+38 vs prior Q) 67 (+14 vs prior Q) +4.7M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
FMR LLC $799,325,570 8,199,893 13.66% Shares
BlackRock, Inc. $401,990,169 4,123,822 6.87% Shares
WELLINGTON MANAGEMENT GROUP LLP $314,848,897 3,229,882 5.38% Shares
Fairmount Funds Management LLC $247,325,379 2,537,191 4.23% Shares
STATE STREET CORP $229,798,634 2,357,440 3.93% Shares
VANGUARD CAPITAL MANAGEMENT LLC $210,514,689 2,159,568 3.60% Shares
Avidity Partners Management LP $205,115,856 2,104,184 3.50% Shares
Octagon Capital Advisors LP $179,525,699 1,841,667 3.07% Shares
TCG Crossover Management, LLC $163,437,308 1,676,624 2.79% Shares
FRED ALGER MANAGEMENT, LLC $126,967,018 1,302,493 2.17% Shares
GEODE CAPITAL MANAGEMENT, LLC $122,696,604 1,258,502 2.10% Shares
Venrock Adviser, LLC $115,026,400 1,180,000 1.97% Shares
UBS Group AG $111,152,545 1,140,260 1.90% Shares
DEERFIELD MANAGEMENT COMPANY, L.P. $109,695,511 1,125,313 1.87% Shares
JENNISON ASSOCIATES LLC $99,601,453 1,021,763 1.70% Shares
Polar Capital Holdings Plc $99,305,410 1,018,726 1.70% Shares
CITADEL ADVISORS LLC $95,034,324 974,911 1.62% Shares
FRANKLIN RESOURCES INC $94,456,440 968,983 1.61% Shares
VANGUARD GROUP INC $84,416,707 2,048,452 1.44% Shares
BAKER BROS. ADVISORS LP $83,068,947 852,164 1.42% Shares
Logos Global Management LP $77,984,000 800,000 1.33% Shares
Cormorant Asset Management, LP $73,110,000 750,000 1.25% Shares
ALLIANCEBERNSTEIN L.P. $70,001,868 834,150 1.20% Shares
BRAIDWELL LP $57,957,904 594,562 0.99% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $55,574,810 570,115 0.95% Shares
AMERIPRISE FINANCIAL INC $51,859,546 531,999 0.89% Shares
Woodline Partners LP $48,793,419 500,548 0.83% Shares
BARCLAYS PLC $42,087,284 431,753 0.72% Shares
MPM BIOIMPACT LLC $40,941,795 420,002 0.70% Shares
NORTHERN TRUST CORP $40,141,386 411,791 0.69% Shares
Affinity Asset Advisors, LLC $38,992,000 400,000 0.67% Shares
SILVERARC CAPITAL MANAGEMENT, LLC $38,017,200 390,000 0.65% Shares
GOLDMAN SACHS GROUP INC $37,253,054 382,161 0.64% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $35,674,073 365,963 0.61% Shares
Bain Capital Life Sciences Investors, LLC $35,333,576 362,470 0.60% Shares
Spruce Street Capital LP $34,587,464 354,816 0.59% Shares
Vivo Capital, LLC $34,507,725 353,998 0.59% Shares
DIMENSIONAL FUND ADVISORS LP $31,334,301 321,503 0.54% Shares
WESTFIELD CAPITAL MANAGEMENT CO LP $30,697,817 314,914 0.52% Shares
VANGUARD FIDUCIARY TRUST CO $29,485,945 302,482 0.50% Shares
Driehaus Capital Management LLC $28,782,530 295,266 0.49% Shares
First Turn Management, LLC $27,856,957 285,771 0.48% Shares
Assenagon Asset Management S.A. $27,357,665 280,649 0.47% Shares
TANG CAPITAL MANAGEMENT LLC $25,802,176 264,692 0.44% Shares
Artisan Partners Limited Partnership $25,176,062 258,269 0.43% Shares
BANK OF AMERICA CORP /DE/ $25,036,081 256,833 0.43% Shares
Bank of New York Mellon Corp $24,993,153 256,393 0.43% Shares
RTW INVESTMENTS, LP $24,181,181 248,063 0.41% Shares
EMERALD ADVISERS, LLC $24,156,031 247,805 0.41% Shares
Pictet Asset Management Holding SA $24,106,317 247,295 0.41% Shares

Show all 284 institutional owners →

Activists & 5%+ owners 4 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin, Tomas Kiselak ×5 filings Nov. 25, 2025 4.90% Amendment · SEC
Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Private Master Fund I LP, Michael Gregory ×4 filings Nov. 19, 2025 4.90% Amendment Passive investment SEC
Viridian, LLC ×2 filings Sept. 12, 2024 · Initial filing · SEC
ATLAS VENTURE FUND X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC ×4 filings Sept. 15, 2023 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 36 insiders · 13 officers · 17 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Marino Garcia CEO AND PRESIDENT Aug. 7, 2026 M 65,292 0 12 $-27,961,831
Ryan Savitz EVP, CFO & CBO July 9, 2026 M 0 0 13 $-14,292,190
Edward Carr CHIEF ACCOUNTING OFFICER Sept. 17, 2026 M 0 0 10 $-5,587,140
Simrat Randhawa EVP, Head of R&D Sept. 1, 2026 M 4,000 0 11 $-15,001,124
Adam M Veness SVP, General Counsel and Sec. Aug. 13, 2026 M 15,000 0 5 $-4,632,790
David Wayne Nichols Chief Technical Officer Aug. 1, 2022 A 14,306 0 0 $0
Lisa Olson Title: Head of Research and Chief Scientific Officer Exhibit 24.1: Power of Attorney Aug. 1, 2022 A 14,264 0 0 $0
Jeffrey Humphrey Chief Medical Officer Aug. 1, 2022 A · 0 0 $0
John C. Davis JR Title: Head of Research and Development and Chief Medical Officer Feb. 11, 2021 A 8,304 0 0 $0
Zoran Zdraveski Title: Secretary and Chief Legal and Technology Operations Officer Feb. 11, 2021 A 133,010 0 0 $0
Christina K. Isacson Chief Business Officer Feb. 10, 2020 A 83,786 0 0 $0
Jason Ryan Title: Chief Operating and Financial Officer Feb. 10, 2020 A · 0 0 $0
COOKE MICHAEL P. Chief Scientific Officer Dec. 2, 2019 S 240,523 0 0 $0
Simon Read Director Aug. 19, 2026 M 0 0 7 $-630,786
Anne Mcgeorge Director Aug. 10, 2026 M 0 0 5 $-844,822
Jonathan Violin Director May 21, 2026 A · 0 0 $0
Paula Soteropoulos Director May 21, 2026 A 0 0 3 $-2,252,895
Steven J. Romano Director May 21, 2026 A · 0 0 $0
Alison Frances Lawton Director May 21, 2026 A · 0 0 $0
MOULDER LEON O JR Director May 23, 2024 A 1,436,745 0 0 $0
Michael Vasconcelles Director Aug. 15, 2022 A · 0 0 $0
David Scadden Director June 28, 2022 A 228,175 0 0 $0
Jeffrey W. Albers Director June 28, 2022 A 4,152 0 0 $0
Thomas O Daniel Director June 28, 2022 A 101,926 0 0 $0
Bruce Booth Director June 28, 2022 A 1,250,000 0 0 $0
Amy L Ronneberg Director June 28, 2022 A 593,611 0 0 $0
Alexis Borisy Director Aug. 26, 2021 J 4,100 0 0 $0
Michael W Bonney Director June 1, 2021 A 215,346 0 0 $0
Blake Byers Director June 5, 2020 A 3,339,137 0 0 $0
Atlas Venture Fund X, L.P. 10% owner Feb. 11, 2021 J 3,148,399 0 0 $0
Sujay Kango · May 21, 2026 A · 0 0 $0
Caren Deardorf · Nov. 30, 2022 A 19,762 0 0 $0
Kristen Stants · Nov. 30, 2022 A 20,264 0 0 $0
Stephen F. Mahoney · Nov. 30, 2022 A 17,264 0 0 $0
Thomas W. Beetham · Nov. 30, 2022 A 19,897 0 0 $0
Jason Gardner · Nov. 30, 2022 A 292,872 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 37 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IBRN · iShares Trust 5.04% 3,652 SH Sept. 11, 2026 Daily
PTH · Invesco Exchange-Traded Fund Trust 1.90% 62,115 SH Oct. 2, 2026 Daily
LABU · Direxion Shares ETF Trust 0.96% 44,156 NS July 31, 2026 N-PORT
BBC · ETFis Series Trust I 0.87% 3,787 NS July 31, 2026 N-PORT
DWAS · Invesco Exchange-Traded Fund Trust … 0.53% 24,335 SH Oct. 2, 2026 Daily
FYC · First Trust Exchange-Traded AlphaDE… 0.44% 52,995 NS July 31, 2026 N-PORT
IWO · iShares Trust 0.32% 444,336 SH Sept. 11, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.27% 50,626 SH Aug. 19, 2026 Daily
PWS · Pacer Funds Trust 0.27% 603 NS July 31, 2026 N-PORT
BKSE · BNY Mellon ETF Trust 0.18% 1,463 NS July 31, 2026 N-PORT
FFSM · FIDELITY COVINGTON TRUST 0.17% 23,108 NS July 31, 2026 N-PORT
RSSL · Global X Funds 0.16% 22,655 NS July 31, 2026 N-PORT
IWM · iShares Trust 0.16% 1,209,461 SH Sept. 11, 2026 Daily
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0.16% 10,325 NS July 31, 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0.15% 29,943 SH Aug. 19, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.14% 272,370 SH Aug. 19, 2026 Daily
FYX · First Trust Exchange-Traded AlphaDE… 0.14% 17,898 NS July 31, 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.09% 4,800 NS July 31, 2026 N-PORT
ESML · iShares Trust 0.06% 16,364 SH Sept. 11, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.06% 17,465 NS July 31, 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.05% 110,607 SH Aug. 19, 2026 Daily
DFAS · Dimensional ETF Trust 0.05% 71,218 NS July 31, 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0.04% 457,520 SH Aug. 19, 2026 Daily
PRFZ · Invesco Exchange-Traded Fund Trust 0.04% 10,691 SH Oct. 2, 2026 Daily
WSML · iShares Trust 0.03% 2,149 SH Sept. 11, 2026 Daily
DCOR · Dimensional ETF Trust 0.01% 3,958 NS July 31, 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0.01% 1,650,280 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.01% 3,889 SH Aug. 19, 2026 Daily
IWV · iShares Trust 0.01% 12,690 SH Sept. 11, 2026 Daily
DFAU · Dimensional ETF Trust 0.01% 7,297 NS July 31, 2026 N-PORT
DFAC · Dimensional ETF Trust 0.01% 27,975 NS July 31, 2026 N-PORT
ITOT · iShares Trust 0.01% 54,499 SH Sept. 11, 2026 Daily
TILT · FlexShares Trust 0.00% 810 NS July 31, 2026 N-PORT
DFUS · Dimensional ETF Trust 0.00% 4,404 NS July 31, 2026 N-PORT
ISCB · iShares Trust · 1,709 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 8,427 SH Sept. 11, 2026 Daily
SMMV · iShares Trust · 2,457 SH Aug. 19, 2026 Daily

DNTH Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 22 analysts BUY
Median target $134.00 +53.4%
10 45.5% Strong Buy
11 50.0% Buy
1 4.5% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

15 analysts · 2026-10-03

Mean target $140.80 +61.2%

← Below all targets Current price $87.33
Low$122.00 Mean$140.80 High$200.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
DNTH $1.78B -9.8 -67.3% -7973.3% -40.8% ·
TVTX $3.47B -131.8 110.5% -5.2% -34.6% ·
PTCT $6.19B 9.8 114.5% 39.4% -331.5% ·
COGT $5.72B -16.4 · · -83.1% ·
ERAS $1.06B -8.5 · · -35.7% ·
RLAY $1.47B -5.3 53.4% -1800.6% -44.9% ·
VKTX $4.04B -11.0 · · -47.3% ·
TNGX $1.20B -10.2 48.3% -162.8% -42.2% ·

Latest News Recent headlines mentioning this company

23
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 Nasdaq · 5 months, 2 weeks ago Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit Nasdaq · 6 months, 2 weeks ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 4, 2026